The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...

The maker of Ozempic and Wegovy found fake 1-milligram injections were being distributed through unauthorized sellers.

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, ...

The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk ...